This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Getty Images milla1cf Fri, 06/07/2024 - 15:10 June 7, 2024 — Calcific aorticvalve disease (CAVD) is the major heart valve disease that afflicts nearly 10 million patients globally with an annual mortality exceeding 100,000, and the numbers continue to rise.
Objective Aortic stenosis (AS) shares pathophysiological similarities with atherosclerosis including active inflammation. CT attenuation of perivascular adipose tissue provides a measure of vascular inflammation that is linked to prognosis and has the potential to be applied to the aorticvalve. HU, p=0.099).
Aortic stenosis (AS) due to fibrosis and calcification of the aorticvalve is a hazardous component of cardiovascular disease burden—after developing symptomatic AS, patients survive for an average of less than 2 years without treatment.
Transcatheter aorticvalve replacement (TAVR) is increasing in popularity for symptomatic severe aortic stenosis. Transfemoral arterial route is the most commonly used approach for TAVR, also known as TAVI or transcatheter aorticvalve implantation.
BackgroundChronic inflammatory disease (CID) accelerates atherosclerosis and the development of aortic stenosis. Data on long‐term outcomes after transcatheter aorticvalve implantation (TAVI) in those patients are missing.
BackgroundAortic stenosis has pathophysiological similarities with atherosclerosis, including the deposition of cholesterol‐containing lipoproteins. The resulting cholesterol crystals activate the NLRP3 (NOD‐like receptor protein 3) inflammasome, leading to inflammation and cardiovascular diseases.
Hutchinson-Gilford Progeria Syndrome (HGPS) is an ultra-rare genetic premature aging disease that is historically fatal in teenage years, secondary to severe accelerated atherosclerosis. With this longer lifespan, calcific aortic stenosis (AS) was identified as an emerging critical risk factor for cardiac death in older patients.
Lp(a) is emerging as an important, yet under-recognized, potential risk factor for cardiovascular disease due to its ability to promote the development of plaques within artery walls, clot formation and aorticvalve calcification. 2022 Aug, 80 (9) 934946 Kronenberg F.
This study examined whether HGF is associated with ECC in the aorticvalve (AVC), mitral annulus (MAC), ascending thoracic aorta and descending thoracic aortic (DTAC). However, knowledge is limited on the role HGF may play in extracoronary calcification (ECC).
years [SD, 4.1]) from the ARIC (Atherosclerosis Risk in Communities) study, we measured segment‐specific PWVs: heart–carotid, heart–femoral, carotid–femoral, heart–ankle, brachial–ankle, and femoral–ankle.
Our perspectives on aortic stenosis (AS) are changing. The pathophysiology of calcific AS (CAS) is complex, yet can be characterised similarly to that of atherosclerosis. In addition, their integration with cardiovascular MRI can provide accurate risk stratification, aiding aorticvalve replacement decision making.
BACKGROUND:High circulating levels of Lp(a) (lipoprotein[a]) increase the risk of atherosclerosis and calcific aorticvalve disease, affecting millions of patients worldwide.
Lipoprotein(a) (Lp[a]) can improve the accuracy of assessment of atherosclerotic cardiovascular disease and the risk of aorticvalve stenosis. Currently, there is no specific treatment to lower its circulating concentration. Raised Lp(a) is a feature of familial hypercholesterolaemia.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content